A61K 47/6891
Pre-targeting systems involving an antibody for targeting specific cells
Official title: {Pre-targeting systems involving an antibody for targeting specific cells}
A61K47/6891 (Pre-targeting systems involving an antibody for targeting specific cells) appears on 550 US grants and 656 published applications in this corpus.
Search patents in A61K- Granted patents
- 550
- Published applications
- 656
- Assignees
- 306
- Inventors
- 1,115
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 2 | 0 |
| 1990 | 2 | 0 |
| 1991 | 1 | 0 |
| 1992 | 4 | 0 |
| 1993 | 3 | 0 |
| 1994 | 4 | 0 |
| 1995 | 3 | 0 |
| 1996 | 10 | 0 |
| 1997 | 18 | 0 |
| 1998 | 28 | 0 |
| 1999 | 20 | 0 |
| 2000 | 15 | 0 |
| 2001 | 15 | 3 |
| 2002 | 16 | 25 |
| 2003 | 10 | 33 |
| 2004 | 5 | 24 |
| 2005 | 16 | 23 |
| 2006 | 10 | 29 |
| 2007 | 17 | 20 |
| 2008 | 7 | 21 |
| 2009 | 17 | 29 |
| 2010 | 15 | 19 |
| 2011 | 17 | 21 |
| 2012 | 14 | 32 |
| 2013 | 22 | 19 |
| 2014 | 18 | 35 |
| 2015 | 29 | 30 |
| 2016 | 34 | 46 |
| 2017 | 26 | 34 |
| 2018 | 27 | 24 |
| 2019 | 20 | 33 |
| 2020 | 15 | 25 |
| 2021 | 21 | 26 |
| 2022 | 12 | 23 |
| 2023 | 17 | 33 |
| 2024 | 19 | 25 |
| 2025 | 7 | 13 |
| 2026 | 13 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Radioligands for pretargeted PET imaging and methods of their therapeutic use15 Sep 2026US 12,734,258 B2Memorial Sloan Kettering Cancer Center
- Chemically cleavable group15 Sep 2026US 12,735,444 B2Tagworks Pharmaceuticals B.V.
- Kidney targeted delivery of drugs1 Sep 2026US 12,721,906 B2The Brigham and Women S Hospital, Inc.
- Meditopes and meditope-binding antibodies and uses thereof25 Aug 2026US 12,714,753 B2City of Hope
- DOTA-hapten compositions for anti-DOTA/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy25 Aug 2026US 12,714,758 B2Memorial Sloan Kettering Cancer Center
- Anti-cancer strain secreting streptavidin-fusion protein having biotin binding ability, anti-cancer composition using the same, anti-cancer adjuvant and tumor imaging agent27 Aug 2026US 2026/0250336 A1Korea Institute of Science and Technology
- Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies13 Aug 2026US 2026/0232834 A1GlaxoSmithKline Intellectual Property Development Limited
- Antibody-drug conjugate targeting claudin18.230 Jul 2026US 2026/0216353 A1Fortvita Biologics (Singapore) Pte. Ltd.
- Multifunctional immunotherapeutic monoclonal antibody complexes and conjugates16 Jul 2026US 2026/0199506 A1
- Vhh polypeptides that bind to light chain (lc) proteases of botulinum neurotoxins (bonts) and methods of use thereof2 Jul 2026US 2026/0184813 A1Trustees of Tufts College
Most cited
By later US patents
- Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells465US 4,975,278 ABristol-Myers Company · 1990
- Intraperative, intravascular and endoscopic tumor and lesion detection and therapy with monovalent antibody fragments180US 5,716,595 AImmunomedics, Inc. · 1998
- Agonist-antagonist combination to reduce the use of nicotine and other drugs177US 5,574,052 A1996
- Targeted combination immunotherapy of cancer175US 6,077,499 AImmunomedics, Inc. · 2000
- Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy173US 6,096,289 AImmunomedics, Inc. · 2000